Source : INDIA TODAY NEWS
Shares of Sun Pharmaceutical Industries Ltd declined over 3% in trade on the Bombay Stock Exchange (BSE), as investor sentiment turned cautious following reports of a potential large acquisition.
At 10:24 am, the stock was trading at Rs 1,655.10, down 3.62%.
The stock came under pressure after a report by The Economic Times said the company is nearing a deal to acquire US-based drugmaker Organon & Co. in a transaction that could be valued at around $12 billion.
advertisement
The proposed deal, if finalised, would be the largest acquisition by Sun Pharma and has raised concerns among investors over the potential impact on the company’s balance sheet.
Market participants are wary of the scale of the transaction and the possibility of increased leverage, especially if the acquisition is funded through significant borrowing.
The size and complexity of integrating a global business like Organon have also added to near-term uncertainty.
While acquisitions can support long-term growth by expanding product portfolios and global presence, they often trigger short-term volatility as markets assess execution risks and returns.
In this case, the sharp reaction in the stock reflects concerns over whether the benefits of the deal will outweigh the financial and operational risks in the near term.
Investors will now watch for official confirmation from the company and further details on deal structure, funding and strategic rationale, which will be key to determining the stock’s direction going forward.
– Ends
Must Watch
SOURCE :- TIMES OF INDIA
